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Mammalian cell surfaces are coated in specific sugar structures, many of which function as antigens and are 
involved in cellular recognition. Important examples are the oligosaccharide A, B, and H antigens present on red 
blood cells that differentiate the A, B and O blood types. Enzymatic cleavage of the GalNAc and Gal residues 
from the cell surface would allow conversion of A and B red blood cells, respectively, to O type. Since Type O 
blood can be universally donated to patients with the same Rh factor, access to efficient enzymes would greatly 
broaden and simplify blood supply. We have sought such enzymes in metagenomic libraries derived from the 






Total DNA was extracted from feces samples, fragmented into chunks containing ~30-40 genes (40-50 kB) and 
transformed into E. coli. After picking colonies into 384 well plates we screened them for enzymes that can be 
used to remove the Gal or GalNAc residues that function as the antigenic determinants from A and B type red 
blood cells, thereby generating “universal” O type blood. A set of efficient enzymes of a new class has been 
identified and characterised and used to convert whole units of A blood to O. These enzymes work 
approximately 30 times faster than any previously characterized and with high specificity. Further, they function 
well in whole blood thus can be hopefully integrated into the current blood processing process. Further we are 
exploring the potential of these enzymes for the removal of A and B antigens from organ surfaces prior to 
transplantation to reduce adverse immune responses. Attempts to engineer these enzymes for improved 
performance will also be presented. 
 
 
